- Home
- IPAR vs RARE Comparison
IPAR vs RARE Comparison
Compare IPAR & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IPAR | RARE |
|---|---|---|
| Founded | 1982 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | 1988 | 2014 |
Fundamental Metrics
Financial Performance| Metric | IPAR | RARE |
|---|---|---|
| Price | $98.24 | $23.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 19 |
| Target Price | ★ $125.50 | $73.11 |
| AVG Volume (30 Days) | 239.1K | ★ 4.0M |
| Earning Date | 02-24-2026 | 02-12-2026 |
| Dividend Yield | ★ 3.27% | N/A |
| EPS Growth | ★ 9.68 | N/A |
| EPS | ★ 5.13 | N/A |
| Revenue | ★ $1,463,838,000.00 | $630,598,000.00 |
| Revenue This Year | $3.14 | $19.68 |
| Revenue Next Year | $1.34 | $19.44 |
| P/E Ratio | $19.10 | ★ N/A |
| Revenue Growth | 3.12 | ★ 20.63 |
| 52 Week Low | $77.21 | $18.41 |
| 52 Week High | $148.15 | $46.50 |
Technical Indicators
Market Signals| Indicator | IPAR | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 76.69 | 38.36 |
| Support Level | $87.64 | $22.00 |
| Resistance Level | $92.00 | $24.65 |
| Average True Range (ATR) | 2.98 | 1.28 |
| MACD | 0.92 | 0.19 |
| Stochastic Oscillator | 86.40 | 44.59 |
Price Performance
Historical ComparisonAbout IPAR Inter Parfums Inc.
Interparfums Inc operates in the fragrance business and produces and distributes a wide array of prestige fragrance and fragrance-related products. It sells its product under the brand which includes Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lacoste, Lanvin, Moncler, Montblanc, Rochas and Van Cleef & Arpels. The company operates in two operating segments namely European based operations, SA, and United States based operations.. The group sells its products to department stores, perfumeries, specialty stores, and domestic and international wholesalers and distributors.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.